Home
Home
  • Home
  • About Us About Us
    • Overview
    • Who we are
    • Why we provide advice
    • What are health technologies
    • Meetings
    • News
    • Who we work with
    • Contact Us
  • What We Do What We Do
    • Overview
    • Our Strategy
    • Work programme
    • Range of advice products
    • Quarterly Bulletin of advice
    • Early HTA Advice Service
  • Our Advice
  • Request Advice Request Advice
    • Overview
    • Form for requesting advice
  • Get Involved Get Involved
    • Overview
    • Contribute to advice
    • NHS boards
    • Patient and Public Involvement
    • Industry Involvement
    • Observe a council meeting
    • DOI Form

SHTG Innovative Medical Technology Overview

  • Home
  • Our Advice
  • Granulox® haemoglobin spray

Title

Output Type

Speciality

Published

Title

Granulox® haemoglobin spray

Output Type

SHTG Innovative Medical Technology Overview

Speciality

Injuries, accidents and wounds

Published

1 August 2016

Key findings

Granulox® was found to be more effective and less costly than standard care.

Three retrospectively controlled cohort studies in patients with diabetic foot ulcers (n=20, active treatment), chronic wounds (n=50) and sloughy wounds (n=100) reported improved wound healing outcomes over a 6 month follow-up. At final follow-up 15 out of 20 diabetic foot ulcer patients treated with Granulox® had complete healing compared to 8 out of 20 controls.

What were we asked to look at?

We were asked to provide a high level overview of Granulox technology. 

Granulox® haemoglobin spray is a Class III medical device indicated for the treatment of chronic wounds, such as venous leg ulcers, arterial leg ulcers, mixed leg ulcers, diabetic foot ulcers, secondary healing of surgical wounds and pressure sores.

Why is this important?

There is a significant burden of a wound on patients’ daily lives; from the physical impact, the psychological impact, to the restrictions on lifestyle. The manufacturer proposes the use of Granulox® for the treatment of chronic venous leg ulcers which have failed to heal with standard care. Granulox® is an add-on treatment option to standard care.

Referred by

infirst HEALTHCARE

Download icon
Download Advice
pdf (197 KB)

Connect with Us

Please let us know if you'd like to receive regular updates on our work.


Last Updated: 31 January 2022

Scottish Health Technologies Group

© 2021, All rights reserved

  • Accessibility
  • Respecting your privacy
  • Cookies
  • Healthcare Improvement Scotland Website
  • Find us on Twitter
  • Freedom of Information

Tell us what you think


We'd love to hear your views

Was our advice useful?  Did you find what you were looking for on our website?